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Abstract
Idiopathic intracranial hypertension is a diagnosis of exclusion defined by elevated intracranial pressure without
mass lesions or hydrocephalus. Causes of idiopathic intracranial hypertension include obesity, vitamin derangements,
antibiotics, corticosteroids, and autoimmune disorders. Cushing’s disease and Addison’s disease have been associated
with idiopathic intracranial hypertension. Secondary adrenal insufficiency following withdrawal of inhaled corticosteroids
has been found to be a relatively common phenomenon. This case describes an 11-year-old boy who was previously
on inhaled corticosteroids for severe asthma who presented with secondary adrenal insufficiency after withdrawal
of steroids. The adrenal insufficiency presented as idiopathic intracranial hypertension. We described the hospital
course and process of diagnosis for this child with secondary adrenal insufficiency following withdrawal of inhaled
corticosteroids. The association between the discontinuation of this patient’s corticosteroids and his onset of headache
suggests secondary adrenal insufficiency as the most likely cause of his idiopathic intracranial hypertension. The gradual
improvement in his symptoms after steroid replacement further supports this. Due to the significant prevalence of
children using inhaled corticosteroids, it is important for clinicians to be aware of the potential for the withdrawal of
these drugs to induce hypothalamic–pituitary–adrenal axis suppression.
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Introduction
Idiopathic intracranial hypertension is a diagnosis of exclusion defined by elevated intracranial pressure in the absence
of any evidence of mass lesions or hydrocephalus. Persistent
headaches, nausea, vomiting, and papilledema are the characteristic signs and symptoms of this condition. It is classically associated with obese females of reproductive age but
is also known to occur in children.1 In addition to obesity,
known causes of idiopathic intracranial hypertension
include vitamin derangements, certain antibiotics, corticosteroids, and autoimmune disorders. Certain endocrine disorders, namely Cushing’s disease and Addison’s disease,
have also been associated with idiopathic intracranial
hypertension.2
Secondary adrenal insufficiency following withdrawal of
inhaled corticosteroids has been found to be relatively common. In a retrospective study, 20.5% of patients on inhaled
corticosteroids were found to have failed their adrenocorticotropic hormone (ACTH) stimulation test after stopping

steroids. The association is highest with higher doses and
duration of treatment.3 The temporal association between the
cessation of this patient’s corticosteroids and his onset of
headache suggests secondary adrenal insufficiency as the
cause of his intracranial hypertension. The gradual improvement in this patient’s symptoms following steroid replacement further supports this. However, this improvement may
not be solely attributed to the steroid replacement as acetazolamide was also given.
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Case report
No approval from an ethical committee or institutional
review board is necessary in our institution for documentation of a case study. Guidelines on patient consent have been
met by obtaining written informed consent from the family.
An 11-year-old Caucasian boy with a past medical history of severe asthma diagnosed at 7 months of age was
admitted to the pediatric service due to severe, persistent
headaches. The headaches had been frequent and severe for
the past 2 months, with the most significant worsening
occurring over the 2 weeks prior to admission. The headaches were described as achy and bitemporal and associated
with nausea and mild photophobia. He reported minimal
relief with sleep. Attempts at pharmacologically treating his
headaches as acute migraines had proved unsuccessful.
Review of the patient’s medical records revealed chronic
use of multiple inhaled corticosteroids for his severe asthma.
The patient has been using a fluticasone inhaler for 5 years
and was started on an additional steroid inhaler, beclometasone dipropionate, 7 months prior to admission. The patient
also has a history of frequent asthma exacerbations requiring hospitalization and oral steroids, with the most recent
episode occurring 3 months prior to the current admission.
Two months prior to the current admission, the patient was
started on a tiotropium bromide inhaler in an effort to discontinue use of his inhaled corticosteroids due to the mother’s concern about the patient’s growth.
His brain magnetic resonance imaging showed a pineal
cyst and Chiari type I malformation, which were incidental
and non-contributory. A lumbar puncture was performed and
revealed an opening pressure greater than 55 cm of cerebrospinal fluid (CSF). CSF studies were within normal limits.
35 mL of CSF were removed during the lumbar puncture,
and closing pressure was recorded to be 15 cm of CSF. The
patient briefly experienced some relief of his headaches after
the lumbar puncture, but he soon began to experience worsening of the headaches on standing with associated dizziness
and vomiting. The patient was started on acetazolamide as
well as topiramate to help relieve the patient’s migranous
symptoms. On ophthalmology consultation, the patient was
also found to have mild to moderate disc edema.
On hospital day 3, the patient began to complain of newonset, generalized abdominal pain. Physical exam revealed
diffuse abdominal tenderness without rebound or guarding.
He was hemodynamically stable and heart rate and blood
pressure were within normal limits. Initial labs, including
electrolytes, amylase, and lipase, were found to be within
normal limits. An abdominal computerized tomography
(CT) was unremarkable, and an abdominal X-ray revealed
mild constipation. Adrenal insufficiency related to withdrawal of inhaled steroids was suspected as a cause of this
patient’s increased intracranial pressure and abdominal pain.
Because of this suspicion, an ACTH stimulation test was
performed and showed blunted production of cortisol. An
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8 AM cortisol level prior to cosyntropin administration was
found to be 3.5 µg/dL. A baseline ACTH level was also
obtained prior to the study and found to be 14.4 pg/mL.
Cortisol levels 30 and 60 min after administration of a standard high dose (250 µg IV) of cosyntropin was administered
were found to be 7.9 and 8.4 µg/dL, respectively. The patient
was subsequently started on a physiologic dose of hydrocortisone at 5 mg three times daily. The hydrocortisone dose was
later increased to 10 mg three times daily due to continued
stress from persistent vomiting.
A repeat lumbar puncture was performed 4 days after initiation of treatment and showed a markedly improved opening pressure at 29.8 cm of CSF. 20 mL of CSF were removed,
and closing pressure was recorded to be 17 cm CSF.
The patient was transferred to a higher-level facility for
more specialized care on hospital day 6. A repeat ophthalmological examination was normal and without any evidence of
papilledema. Both high- and low-dose cosyntropin stimulation tests were repeated and found to be abnormal. He was
started on a steroid taper after 2 days at the new facility and
discharged home 2 days later.

Discussion
Patients with asthma have been found to have adrenal insufficiency not only with high-dose inhaled corticosteroids but
also with low- to medium-dose inhaled corticosteroids when
the inhaled corticosteroids have been given over a long
period.4 One-third of patients on low- to medium-dose
inhaled steroids for an average of 4.5 years showed adrenal
insufficiency.5 In our case, the patient had been on high-dose
inhaled corticosteroids for 5 years, over the maximum dose
recommended for age. He was first on fluticasone propionate
(Advair 230-21, two puffs twice a day). Advair is actually
not recommended for pediatric use at all. He was then on
another brand of fluticasone propionate (Flovent HFA 220,
two puffs twice a day). With Flovent, the maximum dose for
4 to 11 year olds is 176 mcg/day with the maximum dose for
12 years and older being 1760 mcg a day. Our patient was
receiving 880 mcg of Flovent per day. Seven months prior to
admission beclometasone dipropionate (Qvar) 80 mcg one
puff twice a day was also added. Qvar 80 mcg bid is the maximum dose for 5 to 11 year olds.
The occurrence of idiopathic intracranial hypertension
has been reported to be associated with several endocrine
conditions. These include primary adrenal insufficiency,6,7
the medical or surgical treatment of Cushing’s disease,8 and
the use of oral corticosteroids.9 However, very few cases
have been reported describing idiopathic intracranial hypertension resulting from withdrawal of inhaled corticosteroids.10,11 The mechanism by which adrenal insufficiency
induces increased intracranial pressure is not currently wellunderstood. It has been postulated, however, that acute corticosteroid withdrawal induces decreased absorption of CSF
and increased resistance to the flow of CSF.12 Furthermore,
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11β-hydroxysteroid dehydrogenase type 1, an enzyme that
converts inactive cortisone into active cortisol, has been
found to be expressed in the choroid plexus, supporting a
role for cortisol in CSF volume regulation.13

Conclusion
Due to the significant prevalence of children using inhaled
corticosteroids, it is important for clinicians to be aware of
the potential for withdrawal of these drugs to induce hypothalamic–pituitary–adrenal axis suppression. One study suggests the routine performance of annual morning cortisol
levels in asymptomatic patients chronically using inhaled
corticosteroids as an efficient screening tool.3 Furthermore,
it is important for clinicians to recognize idiopathic intracranial hypertension as a rare presentation of adrenal insufficiency due to the damaging potential of this condition in
causing irreversible blindness. When prescribing corticosteroids of any type, clinicians should carefully titrate their dosages to the minimum required to achieve adequate symptom
control.
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